XML 56 R27.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Nature of Operations - Additional Information (Details) $ in Thousands |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Apr. 19, 2017 | Oct. 07, 2016 USD ($) | Jan. 31, 2018 USD ($) | Jul. 31, 2017 USD ($) | May 31, 2017 USD ($) | Aug. 31, 2015 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2015 USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items] |  |  |  |  |  |  |  |
Date of incorporation |  |  |  |  |  |  | Apr. 30, 2004 |
Date of operating commencement |  |  |  |  |  |  | Feb. 29, 2016 |
Share split, conversion ratio | 3.2 |  |  |  |  |  |  |
Shares issued, net of issuance costs |  |  |  |  |  |  |  | $ 21,255
IPO |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements [Line Items] |  |  |  |  |  |  |  |
Shares issued, net of issuance costs |  |  |  |  |  |  | $ 60,772 |
IPO | Nasdaq |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements [Line Items] |  |  |  |  |  |  |  |
Shares issued, net of issuance costs |  |  |  |  | $ 60,800 |  |  |
Secondary Public Offering | Nasdaq | Subsequent Event |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements [Line Items] |  |  |  |  |  |  |  |
Shares issued, net of issuance costs |  |  | $ 64,000 |  |  |  |  |
UroGen Pharma Inc. |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements [Line Items] |  |  |  |  |  |  |  |
Date of operating commencement |  |  |  |  |  |  | Feb. 29, 2016 |
Allergan |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements [Line Items] |  |  |  |  |  |  |  |
Consideration for sales and supporting services |  |  |  |  |  | $ 750 |  |
Consideration received for license and future supply services |  | $ 17,500 |  |  |  |  |  |
Milestone payment for licensing agreement |  |  |  | $ 7,500 |  |  |  |
Allergan | Maximum |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements [Line Items] |  |  |  |  |  |  |  |
Additional milestone payment to be paid |  | $ 207,500 |  |  |  |  |  |

X
- Definition Date when an entity was incorporated + References No definition available. + Details
Name: | dei_EntityIncorporationDateOfIncorporation
Namespace Prefix: | dei_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Additional milestone payment for licensing agreement. + References No definition available. + Details
Name: | urgn_AdditionalMilestonePaymentForLicensingAgreement
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Consideration fee received for license and future supply services. + References No definition available. + Details
Name: | urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consideration for sales and supporting services. + References No definition available. + Details
Name: | urgn_ConsiderationForSalesAndSupportingServices
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment for licensing agreement. + References No definition available. + Details
Name: | urgn_MilestonePaymentForLicensingAgreement
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Organization consolidation and presentation of financial statements. + References No definition available. + Details
Name: | urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems
Namespace Prefix: | urgn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date the operations of the entity commenced, in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_OperationsCommencedDate1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_EntityListingsExchangeAxis=exch_XNCM
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |